BCR-ABL tyrosine kinase inhibitors

A drug may be classified by the chemical type of the active ingredient or by the way it is used to treat a particular condition. Each drug can be classified into one or more drug classes.

BCR-ABL tyrosine kinase inhibitors inhibit the enzyme BCR-ABL tyrosine kinase, which is important in the pathogenesis of chronic myelogenous leukemia (CML).

Chronic myelogenous leukemia occurs due a single genetic abnormality, known as the Philadelphia chromosome. During the translocation when the Philadelphia chromosome is created, a fusion gene called BCR-ABL gene is formed. The BCR-ABL gene encodes for the BCR-ABL tyrosine kinase. The BCR-ABL positive cells in chronic myelogenous leukemia have increased proliferation and resistance to cell death.

BCR-ABL tyrosine kinase inhibitors are used to treat chronic myelogenous leukemia.

Filter by:
Drug Name DownUp( View by: Brand | Generic ) Reviews Ratings DownUp
dasatinib systemic (Pro, More...)
8 reviews
   
Rate it
9.2
imatinib systemic (Pro, More...)
23 reviews
   
Rate it
8.9
nilotinib systemic (Pro, More...)
18 reviews
   
Rate it
8.1
bosutinib systemic (Pro, More...)
0 reviews
   
Rate it
0.0
ponatinib systemic (Pro, More...)
0 reviews
   
Rate it
0.0
Hide
(web1)